RxDoctor Payments Data

Danny Abouekde, DO

Family Medicine · Miami Beach, FLNPI 1386147833

Payments from drug & device makers

$8,351in general payments, 2019–2025

Across 336 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$954
  • Bayer$731
  • AstraZeneca$692
  • Lilly USA, LLC$517
  • Pfizer$438
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,351 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$118,569
Medicare patients
301
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$93,689
MounjaroTirzepatide42$51,497
FarxigaDapagliflozin Propanediol36$33,764
RybelsusSemaglutide14$33,535
EliquisApixaban25$29,354
JardianceEmpagliflozin22$23,806
JanuviaSitagliptin Phosphate14$18,116
Praluent PenAlirocumab15$14,637
LinzessLinaclotide20$14,600
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$7,424
Atorvastatin Calcium388$3,350
Wixela InhubFluticasone Propion/Salmeterol18$2,321
SynthroidLevothyroxine Sodium16$2,154
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,771
Amlodipine Besylate212$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$954$127,22490 claims
Lilly USA, LLCMounjaro$517$51,49742 claims
AstraZenecaFarxiga$692$33,76436 claims
PfizerEliquis$438$29,35425 claims
MerckJanuvia$54$18,11614 claims
AbbVieLinzess, Synthroid$1,015$16,75536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →